Lytix Biopharma AS announced that its licensing partner Verrica Pharmaceuticals Inc. has reported that the last patient has been dosed in Part 2 of the Company's Phase 2 trial of LTX-315 (named VP-315 by Verrica), a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize VP-315 for dermatologic oncology indications. Basal cell carcinoma is a widespread skin cancer, and patients often seek alternatives to surgery due to its associated pain, infection risks, and scarring.

Verrica's VP-315 program is strategically designed to offer a targeted delivery system for the oncolytic peptide VP-315, which is specially engineered to stimulate the patient's immune system and effectively eliminate cancer cells.